What Has Been the Growth Trajectory for the House Dust Mite Allergy Market in Recent Years?
The house dust mite allergy market has seen considerable growth due to a variety of factors.
• The market size for house dust mite allergies has seen significant expansion in the past few years. It will increase from $2.11 billion in 2024 to $2.39 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 13.0%. Factors contributing to this growth during the historic period include heightened awareness and education, advancements in diagnostic tool technology, research initiatives, clinical studies, improvement in healthcare infrastructure, and legislation and standards implementation.
What Can Be Expected from the House Dust Mite Allergy Market Size?
The House Dust Mite Allergy market is expected to maintain its strong growth trajectory in upcoming years.
• The market for house dust mite allergy is set to experience a fast-paced expansion in the coming years. It is anticipated to reach a value of $4.1 billion by 2029, growing at a compound annual growth rate (CAGR) of 14.5%.
This expansion during the projected period can be ascribed to factors such as regulatory backing and allergen labeling, a rise in the incidence of allergies, the adoption of telemedicine and remote care, increased emphasis on precision medicine, and the growth of allergen-avoidance products. Key trends during this forecast period include public health promotion efforts, the incorporation of digital health tools, an emphasis on improving indoor environmental quality, expansion in immunotherapy solutions, and breakthroughs in allergen avoidance products.
What Are the Critical Driver Fuelling The House Dust Mite Allergy Market's Growth?
The house dust mite allergy market is forecasted to expand due to the surge in asthma prevalence. Characterized by constricted airways, swelling and an occasional increase in mucus production that affects the lungs and breathing, asthma makes patients more susceptible to allergies from dust in their surroundings. This intensifies their condition and necessitates more anti-allergic medications. This increases the demand for house dust mite allergy treatments. For example, the Asthma and Allergy Foundation of America, a US-based community organization, reported in September 2024 that approximately 10 people die each day from asthma, leading to a total of 3,235 deaths in 2022 in the U.S alone. These deaths could have been prevented with precise treatment and care. Hence, the rise in asthma diseases fuels the growth of the house dust mite allergy market.
How Is The House Dust Mite Allergy Market segmented?
The house dust mite allergy market covered in this report is segmented –
1) By Product Type: Tablets, Nasal Drops, Injectable
2) By Treatment Type: Medication, Immunotherapy, Nasal Irrigation, Other Types
3) By Diagnosis: Skin Prick Test (SPT), Specific Immunoglobulin E (IgE) Blood Test, Other Diagnosis
4) By Dosage Forms: Solid, Liquid
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Tablets: Sublingual Tablets, Oral Tablets
2) By Nasal Drops: Antihistamine Nasal Drops, Corticosteroid Nasal Drops
3) By Injectable: Allergen Immunotherapy Injections, Corticosteroid Injections
Pre-Book The House Dust Mite Allergy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The House Dust Mite Allergy Market?
Key players in the house dust mite allergy market are prioritizing the creation of innovative solutions like sublingual tablets for managing the growing incidence of these allergies. A sublingual tablet for this ailment is a form of immunotherapy where a tablet is placed under the tongue. The tablet dissolves and releases minimal doses of the allergen causing the allergic reaction. In January 2023, for example, ALK-Abelló A/S, a Danish pharmaceutical company, got FDA approval for ODACTRA. This sublingual tablet is designed to treat house dust mite allergies in teenagers between 12 and 17 years, broadening its earlier application for adult patients. This approval meets a significant requirement, as house dust mites affect nearly half of all allergy victims. The clinical trials have shown that ODACTRA effectively minimizes allergy symptoms and has a comparable safety record to adults. Though the treatment is generally well-received, patients are warned to keep auto-injectable epinephrine accessible due to the risk of severe allergic reactions.
Who Are the Key Players In The House Dust Mite Allergy Market?
Major companies operating in the house dust mite allergy market include:
• Allergy Therapeutics Plc
• Bayer AG
• Catalent Inc.
• GSK Plc
• Merz Pharma GmbH & Co KGaA
• Sanofi S A
• Shionogi & Co. Ltd.
• Stallergenes Greer International AG
• Merck & Co. Inc.
• Torii Pharmaceutical Co. Ltd.
• Ergomed PLC
• DMS Group
• HAL Allergy Group
• Trio Lifescience Private Limited
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Johnson and Johnson Inc.
• Circassia Pharmaceuticals Plc
• Biomay Ag
• GlaxoSmithKline
What Is The Most Dominant Region In The House Dust Mite Allergy Market?
North America was the largest region in the house dust mite allergy market in 2024. Asia-pacific is expected to be the fastest-growing region in the house dust mite allergy market report during the forecast period. The regions covered in the house dust mite allergy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
